Replies to post #153153 on Biotech Values

[DonShimoda]

there are still 4 Tivantinib clinical trials are going including Marquee

you're including the trial that was stopped for futility and the one that stopped enrolling due to the unresolved ILD issue???

it is too early to discuss Roche's Metmab 1st-to-market NSCLC advantage

Ah, hope springs eternal but if MetMab meets its endpoint, Tivantinib would be facing a very expensive head-to-head trial situation.

They could easily enroll and complete the trial in under 2 years but they are not rushing...

MetMab began enrolling its 480 patient, Phase 3 trial in January, so, I suspect it is going to read-out well before then.